ETF Holdings Breakdown of SUPN

Stock NameSupernus Pharmaceuticals Inc
TickerSUPN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS8684591089
LEI549300GRM36VBKISYJ58

News associated with SUPN

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by First Trust Advisors LP
First Trust Advisors LP lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 48.1% in the 4th quarter, Holdings Channel reports. The firm owned 27,019 shares of the specialty pharmaceutical company’s stock after selling 25,048 shares during the period. First Trust Advisors LP’s holdings in Supernus Pharmaceuticals were worth $977,000 […] - 2025-05-08 07:44:59
Barclays PLC Purchases 14,061 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Barclays PLC increased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 12.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 122,849 shares of the specialty pharmaceutical company’s stock after buying an additional 14,061 shares during the period. Barclays PLC’s holdings in Supernus Pharmaceuticals were worth $4,442,000 at […] - 2025-04-28 07:59:03
Raymond James Financial Inc. Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Raymond James Financial Inc. bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 189,364 shares of the specialty pharmaceutical company’s stock, valued at approximately $6,847,000. Raymond James Financial Inc. owned approximately […] - 2025-04-24 07:41:05
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Position Raised by Invesco Ltd.
Invesco Ltd. lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 4.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 508,069 shares of the specialty pharmaceutical company’s stock after acquiring an additional 22,027 shares during the period. Invesco Ltd. owned 0.92% of […] - 2025-04-20 08:22:48
JPMorgan Chase & Co. Acquires 44,414 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
JPMorgan Chase & Co. grew its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 17.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 297,810 shares of the specialty pharmaceutical company’s stock after purchasing an additional 44,414 shares during the quarter. […] - 2025-04-15 07:32:48
Arrowstreet Capital Limited Partnership Purchases 77,393 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Arrowstreet Capital Limited Partnership increased its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 79.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 174,916 shares of the specialty pharmaceutical company’s stock after acquiring an additional 77,393 shares during […] - 2025-04-08 08:01:05
Prudential Financial Inc. Has $2.37 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Prudential Financial Inc. grew its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 14.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 66,733 shares of the specialty pharmaceutical company’s stock after buying an additional 8,352 shares […] - 2025-04-04 07:37:01
Sei Investments Co. Sells 16,825 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Sei Investments Co. cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 5.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 296,915 shares of the specialty pharmaceutical company’s stock after selling 16,825 shares during the period. Sei Investments Co.’s holdings in Supernus Pharmaceuticals were worth $10,736,000 at the end of […] - 2025-03-30 08:37:02
Swiss National Bank Has $3.92 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Swiss National Bank lifted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 0.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,400 shares of the specialty pharmaceutical company’s stock after purchasing an additional 800 shares during the quarter. […] - 2025-03-26 07:44:46
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Monday. Separately, Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. Get Our Latest […] - 2025-03-26 05:58:55
7,978 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Acquired by Atria Investments Inc
Atria Investments Inc bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the 4th quarter, HoldingsChannel.com reports. The fund bought 7,978 shares of the specialty pharmaceutical company’s stock, valued at approximately $288,000. A number of other institutional investors and hedge funds have also bought and sold shares of SUPN. Smartleaf Asset […] - 2025-03-18 08:54:49
Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at StockNews.com
StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a report published on Sunday morning. Separately, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. Check Out Our Latest […] - 2025-03-17 06:33:06
Victory Capital Management Inc. Sells 28,550 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Victory Capital Management Inc. trimmed its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 3.8% during the 4th quarter, HoldingsChannel reports. The firm owned 714,321 shares of the specialty pharmaceutical company’s stock after selling 28,550 shares during the quarter. Victory Capital Management Inc.’s holdings in Supernus Pharmaceuticals were worth $25,830,000 at the end […] - 2025-03-11 08:16:51
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stake Cut by Trust Point Inc.
Trust Point Inc. lessened its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 47.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,521 shares of the specialty pharmaceutical company’s stock after selling 7,812 shares […] - 2025-02-07 10:34:52

SUPN institutional holdings

The following institutional investment holdings of SUPN have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 34,624USD 1,092,041
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 5,201USD 164,040 1.9%
2025-05-08 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 70,235USD 2,215,212
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 26,164USD 825,213
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 26,164USD 825,213 1.9%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 135USD 4,258
Total =162,523 USD 5,125,977
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.